Pneumococcal vaccination for older adults. The first 20 years

Drugs and Aging

Volumn 15, Issue SUPPL. 1, 1999, Pages 21-30

  Fedson, David S ^a  

^a Pasteur Merieux Connaught   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; PROTEIN;

AGED; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; HUMAN; MINER; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SEROTYPE; SIDE EFFECT; STREPTOCOCCUS INFECTION; UNITED STATES; VACCINATION;

EID: 0033379397     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199915001-00003     Document Type: Review

References (43)

1. Kane RL, Grimley Evans JG, Macfayden D, editors. Improving the health of older people. Published on behalf of the World Health Organization. Oxford: Oxford University Press, 1990: 323
2. Austrian R. Douglas RM, Schiffman G, et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976; 89: 184-94
3. Smit P, Oberholzer D, Hayden-Smith S, et al. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977; 238: 2613-6
4. Gaillat J, Zmirou D, Mallard M, et al. Clinical trial of pneumococcal vaccine among institutionalized elderly [French]. Rev Epidemiol Santé Publique 1985; 33: 437-44
5. Simberkoff MS. Cross AP, Al-Ihrahim M, et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 315: 1318-27
6. Koivula I, Stén M, Leinonen M, et al. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med 1997; 103: 281-90
7. Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group Lancet 1998; 351: 399-403
8. Fedson DS, Musher DM, Eskola J. Pneumococcal vaccine. In: Plotkin SA, Orenstein WA. editors. Vaccines. 3rd ed. Philadelphia: WB Saunders Company. 1999: 553-607
9. Fedson DS. The clinical effectiveness of pneumococcal vaccination: a brief review. Vaccine 1999; 17 Suppl. 1: 85-90
10. Clemens JD, Shapiro ED. Resolving the pneumococcal vaccine controversy: are there alternatives to randomized clinical trials? Rev Infect Dis 1984; 6: 589-600
11. Comstock GW. Evaluating vaccination effectiveness and vaccine efficacy by means of case-control studies. Epidemiol Rev 1994; 16: 77-89
12. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 1984; 101: 325-30
13. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325: 1453-60
14. Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993; 270: 1826-31
15. Hirschmann JV, Lipsky BA. The pneumococcal vaccine after 15 years of use. Arch Intern Med 1994; 154: 373-7
16. Hak E, van Essen GA, Grobbee DE, et al. Effectiveness of pneumococcal vaccine [letter]. Lancet 1998; 351: 1283
17. Mansion BJ, Plouffe JF, File Jr TM, et al. Incidence of community-acquired pneumonia requiring hospitalization. Arch Intern Med 1997; 157: 1709-18
18. Smith MD, Stuart J, Andrews NJ, et al. Invasive pneumococcal infection in South and West England. Epidemiol Infect 1998; 120: 117-23
19. Fedson DS, Scott JAG. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 1999; 17 Suppl. 1: 11-8
20. Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcat bacteremia among elderly people. JAMA 1997; 278: 1333-9
21. Fedson DS. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness. Semin Respir Infect 1993; 8: 285-93
22. Fedson DS, Hirota Y, Shin HK, et al. Influenza vaccination in 22 developed countries: an update to 1995. Vaccine 1997; 15: 1506-11
23. Fedson DS. Pneumococcal vaccination in the United States and 20 other developed countries, 1981-1996. Clin Infect Dis 1998; 26: 1117-23
24. Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination levels among adults ≥ 65 years -United States, 1997. MMWR 1998; 47: 797-802
25. Fedson DS. The changing use of pneumococcal vaccine in developed countries. Can J Infect Dis 1999; 10 Suppl. A: 60A-4
26. Watkins J. Pneumococcal vaccine use by UK doctors [abstract]. First International Symposium on Pneumococci and Pneumococcal Diseases; 1998 Jun 13-17; Elsinore, Denmark: 79
27. Sankilampi U, Honkanen PO, Bloigu A, et al. Persistence of antibodies to pneumococcal capsutar polysaccharide vaccine in the elderly. J Infect Dis 1997; 176: 1100-4
28. Jackson LA, Benson P, Sneller V-P, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999; 281: 243-8
29. Dagan R, Muallem M, Melamed R, et al. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid of diphtheria toxoid. Pediatr Infect Dis J 1997; 16: 1060-4
30. Black S, Shinefield H, Ray P, et al. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth-Lederle) in 37,000 infants and children: results of the Northern California Kaiser Permanente Efficacy Trial [abstract LB9]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27: San Diego
31. Powers DC, Anderson EL, Lottenbach K, et al. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis 1996; 173: 1014-8
32. Chan CY, Molrine DC, George S, et al. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis 1996; 173: 256-8
33. Vernacchio L, Neufeld FJ, MacDonald K, et al. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease. J Pediatr 1998; 133: 275-8
34. Antilla M, Eskola J, Käyhty H. Opsonic activity and concentration of antibodies to Streptococcus pneumoniae type 6B polysaceharide [abstract]. 35th Annual Meeting of the Infectious Diseases Society of America; 1997 Sep 13-16; San Francisco: 183
35. Vidarsson G, Sigurdardottir ST, Gudnason T, et al. Isotypes and opsonophagocytosis of pncumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine. Infect Immun 1998; 66: 2866-70
36. Fedson DS, Henrichsen J, Mäkelä PH, et al. Immunization of elderly people with polyvalent pneumococcal vaccine. Infection 1989; 17: 437-41
37. Riley ID, Tarr PI, Andrews M, et al. Immunisation with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet 1977; 1: 1338-41
38. Kirkwood BR, Gove S, Rogers S, et al. Potential interventions for the prevention of childhood pneumonia in developing countries: a systematic review. Bull World Health Organ 1995; 73: 793-8
39. Mulholland, EK. A new research strategy for accelerating development of pneumococcal vaccines. A report prepared for the Scientific Advisory Group of Experts, Global Programme for Vaccines and Immunisation. Geneva: World Health Organisation, 1997
40. Hausdorff WP. Prospects for the use of new vaccines in developing countries: cost is not the only impediment. Vaccine 1996; 14: 1179-86
41. Briles DE, Tart RC, Swiatlo E, et al. Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA). Clin Microbiol Rev 1998; 11: 645-57
42. Paton JC. Novel pneumococcal surface proteins: role in virulence and vaccine potential. Trends Microbiol 1998; 6: 85-7
43. French N, Nakiyingi J, Carpenter L, et al. Lack of efficacy of 23-valent pneumococcal polysaccharide vaccine in HIV-I-infected Ugandan adults [abstract]. In: Pneumococcal vaccines for the world 1998; Washington DC, 1998